Variable | aCategory | LBW % (n) | Unadjusted OR (95% CI)b | Adjusted OR (95% CI)c | p-value |
---|---|---|---|---|---|
Setting | Semi-rural (190) | 12.1 (23) | 7.62 (2.59–22.52) | 5.29 (1.35–16.15) | 0.003 |
Semi-urban (79) | 1.8 (4) | REF | REF | ||
Age group (years) | < 21 (79) | 6.3.(5) | 0.6 (0.20–1.86) | 0.84 (0.19–3.71) | 0.822 |
21–25 (128) | 10.2 (13) | 4.38.(1.79–10.71) | 2.22 (0.72–6.89) | 0.166 | |
> 25 (209) | 4.3 (9) | REF | REF | ||
Parity | Primiparae (122) | 8.2 (10) | 1.46 (0.59–3.63) | 1.37 (0.39–4.83) | 0.626 |
Secundiparae (120) | 5.8 (7) | 1.0 (0.37–2.70) | 1.04 (0.30–3.63) | 0.955 | |
Multiparae (174) | 5.8 (10) | REF | REF | ||
PM infection | Positive (75) | 12.0 (9) | 2.45 (1.05–5.68) | 2.33 (0.90–6.07) | 0.083 |
Negative (341) | 5.3.(18) | REF | REF | ||
Anaemic status | Anaemic (265) | 9.4 (25) | 7.71 (1.8–33.02) | 4.60 (1.03–20.57) | 0.046 |
Non-anaemic (150) | 1.3 (2) | REF | |||
IPTp-SP dosage frequency | ≥ 3 SP dose (180)) | 4.4 (8) | 0.40 (0.16–1.0) | 0.31 (0.11–0.87) | 0.027 |
2 SP dose (140) | 4.3 (6) | 0.29 (0.11–0.79) | 0.32 (0.11–0.93) | 0.036 | |
≤ 1 dose (96) | 13.5 (13) | REF | REF | ||
ITN usage | Yes (280) | 6.1 (17) | 1.23 (0.55–2.76) | 1.15 (0.46–2.87) | 0.762 |
No (136) | 7.4 (10) | REF | REF |